Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pBABEpuro-ERBB2 Citations (11)

Plasmid Article: Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. Epub 2012 Aug 20.
PubMed Journal

Articles Citing pBABEpuro-ERBB2

Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. Garay C, Judge G, Lucarelli S, Bautista S, Pandey R, Singh T, Antonescu CN. Mol Biol Cell. 2015 Oct 1;26(19):3504-19. doi: 10.1091/mbc.E14-09-1412. Epub 2015 Aug 5. PubMed
Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells. Huang WC, Burnouf PA, Su YC, Chen BM, Chuang KH, Lee CW, Wei PK, Cheng TL, Roffler SR. ACS Nano. 2016 Jan 26;10(1):648-62. doi: 10.1021/acsnano.5b05661. Epub 2016 Jan 13. PubMed
The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ. Papadakis ES, Barker CR, Syed H, Reeves T, Schwaiger S, Stuppner H, Troppmair J, Blaydes JP, Cutress RI. Oncogenesis. 2016 Apr 4;5:e215. doi: 10.1038/oncsis.2016.10. PubMed
Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Ferreira RB, Wang M, Law ME, Davis BJ, Bartley AN, Higgins PJ, Kilberg MS, Santostefano KE, Terada N, Heldermon CD, Castellano RK, Law BK. Oncotarget. 2017 Apr 25;8(17):28971-28989. doi: 10.18632/oncotarget.15952. PubMed
A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR. Song X, Qi X, Wang Q, Zhu W, Li J. Am J Cancer Res. 2017 Sep 1;7(9):1884-1898. eCollection 2017. PubMed
Proteasome inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. Thaler S, Schmidt M, Robetawag S, Thiede G, Schad A, Sleeman JP. Oncotarget. 2017 Aug 14;8(42):72281-72301. doi: 10.18632/oncotarget.20261. eCollection 2017 Sep 22. PubMed
Progesterone impairs Herceptin effect on breast cancer cells. Kitowska K, Kowalska A, Mieszkowska M, Piasecka D, Skladanowski AC, Romanska HM, Sadej R. Oncol Lett. 2018 Feb;15(2):1817-1822. doi: 10.3892/ol.2017.7493. Epub 2017 Nov 27. PubMed
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Shin DH, Jo JY, Han JY. Mol Cancer Ther. 2018 Sep;17(9):2024-2033. doi: 10.1158/1535-7163.MCT-17-1178. Epub 2018 Jun 29. PubMed
A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Wang M, Ferreira RB, Law ME, Davis BJ, Yaaghubi E, Ghilardi AF, Sharma A, Avery BA, Rodriguez E, Chiang CW, Narayan S, Heldermon CD, Castellano RK, Law BK. Oncogene. 2019 May;38(22):4264-4282. doi: 10.1038/s41388-019-0717-6. Epub 2019 Feb 4. PubMed
Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Ahn S, Li J, Sun C, Gao K, Hirabayashi K, Li H, Savoldo B, Liu R, Dotti G. Cancer Immunol Res. 2019 May;7(5):773-783. doi: 10.1158/2326-6066.CIR-18-0636. Epub 2019 Mar 6. PubMed
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K. Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32408. PubMed

If you have published an article using this plasmid, please email us at [email protected] to have your article added to this page.